Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab pegol in children and adolescents with polyarticular-course juvenile idiopathic arthritis
2009-018027-33Phase 3
- Sponsor
- UCB
- Start
- Aug 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of certolizumab pegol in juvenile idiopathic arthritis (JIA), sponsored by UCB. Primary endpoint: Certolizumab pegol plasma concentration at Week 16.
02
Drugs
certolizumab pegol
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2009-018027-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018027-33.